ADMA Biologics Inc (ADMA)

Return on equity (ROE)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	-28,239	-65,904	-71,648	-75,749	-48,279
Total stockholders’ equity	US$ in thousands	135,206	151,974	141,173	88,249	26,193
ROE		-20.89%	-43.37%	-50.75%	-85.84%	-184.32%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $-28,239K ÷ $135,206K
= -20.89%

ADMA Biologics Inc's return on equity (ROE) has shown significant fluctuations over the past five years, with negative ROE figures ranging from -184.32% in 2019 to -20.89% in 2023. This indicates that the company has been facing challenges in generating profits relative to its shareholder equity. The decreasing trend in ROE from 2019 to 2023 may suggest ongoing operational inefficiencies or financial difficulties impacting the company's ability to generate returns for its shareholders. Investors and stakeholders may be concerned about the company's ability to effectively utilize its equity to generate profits based on the downward trend in ROE. Further analysis of the company's financial performance and strategic initiatives may be necessary to address the underlying factors contributing to the negative ROE figures.